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Fractional flow reserve versus angiography in guiding
management to optimize outcomes in non–ST-elevation
myocardial infarction (FAMOUS-NSTEMI): Rationale
and design of a randomized controlled clinical trial☆
Colin Berry, MD, PhD, a,b Jamie Layland, MD, a,b Arvind Sood, MD, c Nick P. Curzen, BM (Hons), PhD, d
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Andrew H. Briggs, PhD, i Ian Ford, PhD, j and Keith G. Oldroyd, MD (Hons) a Glasgow, East Kilbride, Southampton,
Blackburn, Newcastle, Sunderland, and Nottingham, United KingdomBackground In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually
recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of
coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic,
clinical, and health economic utility as compared with angiography-guided standard care.
Methods and design Aprospectivemulticenter parallel-group1:1 randomized controlled superiority trial in350NSTEMI
patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized
immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR
measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will
be disclosed to guide treatment in the FFR-guided group but not disclosed in the “angiography-guided”group. In the FFR-guided group,
an FFR ≤0.80will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as
appropriate. The primary outcome is the between-group difference in the proportion of patients allocated tomedicalmanagement only
compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial
infarction or heart failure, quality of life, and health care costs. Theminimumandaverage follow-upperiods for the primaryanalysis are
6 and 18 months, respectively.
Conclusions Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the
influence of FFR disclosure on treatment decisions and health and economic outcomes. (Am Heart J 2013;166:662-668.e3.)From the aWest of Scotland Heart and Lung Centre, Golden Jubilee National Hospital,
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Acute non–ST-elevationmyocardial infarction (NSTEMI)
is the commonest form of acute coronary syndrome
(ACS) and a leading global cause of premature mor-
bidity and mortality.1 A coronary angiogram is recom-
mended in intermediate- to high-risk NSTEMI patients to
detect obstructive coronary artery disease (CAD) and so
identify patients who may benefit from coronary
revascularization.1-3 In ACS patients, stress testing
before invasive management is not recommended1,3;
and so functional information on ischemia is usually not
available. Usual care is based on visual interpretation of
coronary disease severity revealed by the angiogram;
and treatment decisions include medical therapy,
percutaneous coronary intervention (PCI), or coronary
artery bypass surgery (CABG). Because visual assess-
ment of the angiogram may be inaccurate, judgments
made by cardiologists in everyday practice are subjective,
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ment decisions.4-6
Recent studies (DEFER,7 FAME,8 FAME II9) in patients
with stable CAD have presented a new approach to the
management of CAD. Fractional flow reserve (FFR) is
an index of the physiological significance of a coronary
stenosis and is defined as the ratio of maximal blood
flow in a stenotic artery to normal maximal flow.7-12 An
FFR ≤0.80 is an evidence-based physiological threshold
that correlates with the presence of inducible ischemia
on noninvasive testing.11,12 Alternatively, an FFR N0.80
indicates that patients can be managed safely with medical
therapy. DEFER7 and FAME8 highlighted the benefits of
FFR measurement in stable CAD to more accurately
identify flow-limiting stenoses and guide PCI, leading to
improved outcomes and reduced costs10 compared with
angiography alone. Overall, FFR measurement can identify
and exclude obstructive CAD with high diagnostic
accuracy,11-13 including in patients with prior MI.12FFR measurement in unstable CAD
Fractional flow reserve measurement requires maxi-
mal coronary hyperemia that theoretically may be less
readily achieved in patients with recent MI because of
microvascular injury.14,15 However, some recent stud-
ies support the notion that FFR measurements are
valid in medically stabilized MI patients.16-20 Ntalianis
et al16 measured FFR in 112 nonculprit coronary
lesions repeatedly (average interval 35 ± 4 days) in
101 patients with recent acute MI and found similar
FFR values at each time point. In one other study, FFR
correctly identified inducible ischemia on single
photon emission computed tomography in 57 patients
N6 days after MI15; and in a follow-up study of 124
ACS patients, deferring revascularization in lesions
with an FFR ≥0.75 was safe.17 In hospitalized patients
with recent MI, FFR-guided management is associated
with lower in-hospital costs compared with deferred
management guided by myocardial stress perfusion
scintigraphy.18 Based on invasive measurement of
coronary vasodilator capacity, we have recently
shown that vasodilator reserve is similar in patients
with stable angina and NSTEMI, consistent with
preserved coronary vasodilator capacity in medically
stabilized NSTEMI patients.19 Finally, nearly one-third
of the patients randomized in FAME had a history of
medically stabilized unstable angina or NSTEMI 5 or
more days from randomization (or b5 days if the peak
creatine kinase was b1,000 IU)20; and the benefit of
FFR-guided PCI was similar in patients with unstable
versus stable coronary disease.20 The FAME investiga-
tors concluded that their post hoc analysis could not
prove equivalence of effects between subgroups
because FAME8 was neither designed nor powered
to do so.Therefore, the potential diagnostic, prognostic, and
health economic impact of FFR measurement to inform
the management of unselected patients with recent
medically stabilized NSTEMI has not been established.
Specific uncertainties with angiography-guided
treatment decisions in NSTEMI
First, treatment decisions for nonobstructive (FFR N0.80)
culprit coronary lesions lack an evidence base to guide
management.1,2 On the one hand, a stent for coronary
plaque rupture might reduce the risk of recurrent thrombo-
sis. On the other hand, optimal medical therapy with dual
antiplatelet drugs and high-dose statins might suffice; and
unnecessary stenting can be harmful (eg, stent thrombosis,
restenosis). Second, in NSTEMI patients with multivessel
coronary disease, evidence is lacking as to whether
nonculprit obstructive lesions should undergo revascular-
ization or not.1,2 A post hoc analyses of the contemporary
large-scale ACUITY trial found that incomplete coronary
revascularization was a multivariable predictor of major
adverse cardiac events at 1 year and that the risk was
related to the number of nonrevascularized lesions.21 In a
recent analysis of NSTEMI patients in whom FFR was
measured during usual care in our hospital, we found
that FFR disclosure influenced cardiologists' treatment
decisions.22
Rationale for a trial of FFR-guided management versus
angiography alone in NSTEMI
First, FFR measurement is not a current standard of care
in NSTEMI patients.1-3
Second, the prognostic relationship between FFR values
and clinical outcomes in NSTEMI patients is uncertain and
may not be the same as in patients with stable coronary
disease.14 Therefore, to study the prognostic importance
of FFR, it will be measured in all patients and disclosed in
the FFR-guided group but not disclosed in the angiogra-
phy-guided control group. Because all patients will be
followed up for clinical events, the relationships between
FFR and health outcomes (composite cardiovascular
events) will be evaluated.
Third, because stress testing is not generally appropri-
ate in patients with recent MI, FFR-guided management
could obviate the need for “deferred” management.18
Fourth, FFR has the potential to guide revascularization of
culprit and nonculprit lesions. Because there are no data to
support stenting in nonobstructive culprit lesions, we
propose that the treatment decisions are consistently guided
by the FFR values in both culprit and nonculprit lesions using
the established FFR threshold of 0.80 for revascularization.
Non–flow-limiting lesions (FFRN0.80)would be treatedwith
optimal medical therapy,1 and flow-limiting lesions (FFR
≤0.80) should be revascularized by PCI or CABG.
Fifth, when stenting is performed, the poststent FFR
can be used to ensure that an optimal stent result is
Figure 1
Flow diagram of the trial.
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nonculprit lesions treated by PCI.23
Study hypothesis
Our first hypothesis is that routine FFR measurement
increases the proportion of NSTEMI patients that will be
managed medically. Our second hypothesis is that
routine FFR measurement in NSTEMI patients is feasible
and has additive diagnostic, clinical, and health economic
utility compared with standard care based on visual
assessment of the angiogram.
Methodology
Primary aim
The primary aim is to determine if the treatment and
outcomes of NSTEMI patients whose management is
guided by FFR disclosure differ compared with those of
patients whose treatment is guided by visual interpretation
of the angiogram alone (FFR measured, not disclosed).
Secondary aims
The secondary aims are (1) to determine the feasibility
and safety of routine FFR measurement in NSTEMI, (2) to
determine the level of agreement between functional
(FFR) and visual assessments of coronary disease severity
in NSTEMI patients, (3) to determine the relationships
between FFR values during the baseline procedure (and
receiver operating characteristic) and cardiac events
during follow-up in all patients, (4) to provide preliminary
data on whether FFR-guided management is associated
with improved health outcomes and quality of life in the
longer term compared with angiography-guided treatment
decisions, and (5) to perform a health-economic analysis.
Standard care of NSTEMI patients in the National
Health Service. The participating hospitals adhere to
current guidelines for optimal medical therapy1,3 and
optimal revascularization.1-3 A left main stenosis of ≥50%
and an epicardial coronary stenosis N70% are usually
taken to be obstructive lesions for which revasculariza-
tion should be considered.1,2 In contemporary practice,
FFR is only measured in a minority of patients (b10% of
patients overall22,24) and is not standard care. Patients
who may be candidates for CABG will be discussed at the
Multidisciplinary Heart Team meeting in each center. If
staged PCI is planned, then all procedures should take
place during the index hospitalization.
Setting and design. A prospective multicenter
parallel-group 1:1 randomized controlled superiority trial
will be conducted in 6 UK centers including 3 academic
cardiothoracic centers and 3 nonacademic regional
hospitals (Figure 1). The first patient was randomized on
October 25, 2011; and the trial is expected to complete
follow-up in November 2013 (Figure 2).
Study population. We estimate that approximately
1,400 consecutive NSTEMI patients with a clinical diagno-sis of confirmed or suspected type 1 MI25 will be screened
before coronary angiography. An NSTEMI is defined
according to the occurrence of acute ischemic symptoms
(eg, chest discomfort) and elevated cardiac biomarkers but
without ST-segment elevation on the electrocardiogram.25
Type 1 represents spontaneous MI due to a reduction in
myocardial blood flow secondary to atherosclerotic plaque
rupture and/or coronary thrombosis in one or more
arteries.25 Although underlying coronary disease is usually
present, there may be mild or no coronary disease. The
inclusion and exclusion criteria are described in Table.
Patients who give informed consent but who are not
randomized will be included in a registry. The reasons for
exclusion from the trial after consent but before random-
ization (eg, coronary angiogram findings) and inclusion in
the registry will be prospectively recorded. Similar
information will be collected in the registry and random-
ized patients, including during follow-up. We aim to
maximize participant retention and follow-up through
telephone contact and use of national electronic databases
for long-term follow-up.
Catheter laboratory study protocol. Once the
coronary angiogram has been obtained, the cardiologist
Figure 2
Gantt chart.
Table. FAMOUS NSTEMI study design
Inclusion criteria
Medically stabilized NSTEMI with an elevated troponin (Nupper limit of
normal for local reference range) with ≥1 risk factor for CAD (eg,
diabetes, age N65 y, prior CAD, prior peripheral vascular disease,
hypertension, hyperlipidemia, family history of CAD)
≥1 noncritical coronary stenosis ≥30% severity with normal coronary
blood flow (Thrombolysis in Myocardial Infarction grade III) in which FFR
measurement might have diagnostic value
Invasive management within 72 h of hospital admission or a history of
recurrent ischemic symptoms within 5 d
Exclusion criteria
Ongoing ischemic symptoms not controlled by medical therapy
Cardiogenic shock or hemodynamic instability
Angiographic exclusion: highly tortuous or calcified arteries, left main
stenosis N80% (ie, consistent with severe left main disease)
Life expectancy of b1 y
MI with persistent ST elevation
Intolerance to antiplatelet drugs
Unsuitable for either PCI or CABG on clinical or angiographic grounds
CAD b30% reference vessel diameter
Noncoronary cardiac surgery (eg, an indication for concomitant valve
repair or replacement)
Inability to give informed consent
Age b18 y (no upper age limit)
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randomized based on angiographic criteria (Table).
The main angiographic inclusion criterion is the
presence of one or more noncritical coronary stenoses
≥30% severity that are associated with (1) normal
coronary blood flow (ie, Thrombolysis in Myocardial
Infarction grade III), (2) amenable to revascularization by
PCI or CABG, and (3) FFR measurement is feasible and
may have diagnostic value (Table). A minimum stenosisseverity of 30% is adopted for FFR measurement in our
study because visual assessment of the angiogram may
underestimate stenosis severity. Inclusion of a more
severe stenosis (eg, N90% severity) is permissible
provided the cardiologist believes FFR has the potential
to influence the treatment decision based on coronary
and patient characteristics. Left main stem disease is
included. The pressure wire (Certus, St Jude Medical,
Uppsala, Sweden) will be used in all patients to provide
an FFR value across all coronary narrowings ≥30%
severity as appropriate. Our aim is to maximize inclusion
of eligible patients to minimize selection bias.
Assessment of the coronary angiogram and
recording of the initial treatment decision. Once
the coronary angiogramhas been obtained, the cardiologist
will report the severity of all coronary lesions as N or b70%
of the reference vessel diameter (50% for left main) based
on visual interpretation of the angiogram and in line with
usual care. The cardiologist will then establish an intended
treatment plan based on all of the available clinical
information and the angiogram findings. The cardiologist's
interpretation of the diagnostic angiogram and the
treatment plan will then be recorded at that time in the
catheter laboratory. Therefore, the initial treatment deci-
sion will be established before randomization or treatment
group assignment is known and before the pressure wire is
passed into the coronary arteries. Therefore, no FFR
measurements will be acquired before randomization.
Randomization. Once the coronary angiographic
findings and treatment plan have been recorded and if, in
the opinion of the treating cardiologist, the patient remains
eligible to continue in the study, randomizationwill then be
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the catheter laboratory using a Web-based computer
randomization tool provided by the independent Clinical
Trials Unit. The randomization sequencewas created using
the method of randomized permuted blocks.
Patients who had consented but were ineligible on
angiographic criteria will be entered into a registry.
FFR measurement
Myocardial FFR measurement is described in the online
Appendix Supplementary material.
FFR-guided group
Fractional flow reserve will be measured by the
cardiologist immediately after randomization, and the FFR
result will used to guide treatment decisions based on a
threshold of 0.80. An FFR≤.80 should result in a treatment
decision for revascularization by PCI or CABG combined
with optimal medical therapy; and an FFR N0.80 should
result in treatment with optimal medical therapy alone, in
line with contemporary guidelines for optimal secondary
prevention drug therapies, cardiac rehabilitation, and risk
factor modification.1 Any changes in treatment following
FFR disclosure compared with the initial treatment plan
prior to FFR disclosure will be recorded.
Angiography-guided group and blinding
In patients randomized to the angiography-guided
group, the RadiAnalyzer Xpress (St Jude Medical) will
be turned out of view by the research team such that it is
impossible for the clinical team to see the pressure wire
recording. The pressure wire recording will not be
displayed on any other monitor in the catheter laborato-
ry, and the clinicians and patients will not know the
results. When the coronary pressure display is out of view
of the clinical team, the cardiologist will then measure
FFR as described above, guided by the research staff who
will monitor and record the pressure wire data.
Therefore, the patient and the clinical team responsible
for the patient, including the interventional cardiologists
and nurses, will be blinded to the pressure wire
recording. Quality control checks, including assessments
of equalized pressure recordings and verification of
symptoms and hemodynamic changes with intravenous
adenosine, will be conducted in the usual way, with the
guidance of the unblinded research team. These steps
will be followed for all FFR measurements.
Quality assurance procedures are described in the
online Appendix Supplementary material.
End points
Primary outcome
The between-group difference is the proportion of
patients allocated to medical therapy only instead ofrevascularization at baseline. The treatment decision will
be made by the clinical team in the cardiac catheter
laboratory during the index procedure or shortly
afterward during the index hospitalization including
when a multidisciplinary heart team review is indicated.
Secondary outcomes
1) The safety and feasibility of routine FFR measure-
ment at baseline.
2) The percentage rate of discordance between an FFR
≤ or N0.80 and coronary stenosis severity (stenosis N
or b70% of reference vessel diameter [50% for left
main] assessed visually in all patients in the catheter
laboratory before randomization);
3) Major adverse cardiac events are defined as cardiac
death or hospitalization for MI or heart failure after
randomization. Therefore, emphasis has been placed
on “spontaneous” “hard” outcomes. Because the
decision for revascularization may be susceptible to
bias, this event is not included in the primary
outcome. Information on hospitalizations for other
adverse events (ie, unstable angina, renal failure,
stroke, PCI, CABG) will be prospectively recorded.
The prognostic value of FFR in all patients for subsequent
adverse events will be assessed. The outcomes will be
assessed during the study until the final randomized patient
has completed aminimum of 6months of follow-up. The 3-
year event rates will also be assessed.
4) Health care costs (including revascularization proce-
dures, stents, bed days) will be prospectively recorded
for the index and any subsequent hospitalizations.
5) Quality of life (EuroQoL, EQ-5D).Statistical methods
The sample size calculation and pilot data22 statistical
and health economic28,29 analyses plans are described in
the online Appendix Supplementary material.
Follow-up and timetable
A quality-of-life assessment will be completed at
6-month intervals (EuroQoL, EQ-5D). Clinical follow-up
will continue for an average of 1.5 years (range 6-30
months). Follow-up assessments for adverse events will
be performed by the clinical research staff by telephone
or in person (eg, outpatient clinic review), as appropri-
ate. Medical records will also be checked. Follow-up
contact will occur at 6 monthly intervals until the last
patient has achieved a minimum of 6 months of follow-
up. Follow-up in the longer term will be supported by
electronic record linkage with central government health
records. The active phase of the project is intended to last
about 30 months.
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FAMOUS-NSTEMI has full UK National Research Ethics
Service approval (Reference 11/S0703/6).
Registration
The trial registration numbers are: NCT01764334;
ISRCTN97489534.
Trial management. The trial will be conducted in line
with Guidelines for Good Clinical Practice in Clinical
Trials.30 Trial management will include a Trial Manage-
ment Group, Trial Steering Committee, Clinical Event
Committee, and Data and Safety Monitoring Board (online
Appendix Supplementary material).31
Definition of adverse events
1) Major adverse cardiovascular event is the composite
of “cardiovascular death, nonfatal MI, unplanned
hospitalization for transient ischemic attack or stroke.”
2) Major adverse cardiac events are defined as “cardiac
death, or unplanned hospitalization for MI or heart
failure.”
Percutaneous coronary intervention and CABG are
nonmajor adverse events.
3) Myocardial infarction is defined according to the
criteria specified in the Third Universal Definition of
Myocardial Infarction (including type 4 MI for PCI
and type 5 for CABG).25
4) Contrast agent–induced nephropathy is defined as
either a N 25% increase of serum creatinine or an
absolute increase in serum creatinine of 0.5mg/dL after
a radiographic examination using a contrast agent.32
5) Bleeding is defined according to theACUITY criteria33:
major bleed = intracranial or intraocular bleeding,
bleeding at the site of angiography requiring
intervention, a hematoma of 5 cm in diameter, a
reduction in hemoglobin level of at least 4 g/dL in the
absence of overt bleeding or 3 g/dL with a source of
bleeding, or transfusion.
Sources of funding
The trial is supported by a Project Grant from the
British Heart Foundation (PG/11/55/28999) and the Chief
Scientist Office of the Scottish Government. St Jude
Medical UK Ltd has provided a restricted research grant
for the pressure wires.
The trial sponsor is the National Waiting Times Centre,
NHS Scotland. The authors are solely responsible for the
design and conduct of the study, all analyses, the drafting
and editing of the paper, and its final contents.
Discussion
Should our hypotheses prove correct, then favorable
outcomes from our developmental clinical trial willinform the design and justification for undertaking a
large multicenter outcome trial to further validate these
initial findings.
Randomization is performed after coronary anatomy is
known because coronary lesion severity defines the
patients who are eligible to be randomized. However,
this design renders the trial susceptible to selection bias,
as may have occurred in other trials (eg, COURAGE,
BARI2D, FAME, and FAME-2), potentially favoring
inclusion of patients with less complex coronary
disease. To facilitate inclusion of patients with complex
disease (eg, chronic total occlusion, critically narrowed
lesions), an FFR of 0.5 can be assigned without
requirement to pass the pressure wire. This approach
is intended to facilitate the inclusion of all eligible
patients. Because FFR group assignment is “open,” by
design, we have attempted to minimize treatment bias at
the time of the procedure and during follow-up by not
disclosing the FFR values in the angiography-guided
group. Nondisclosure of FFR in the control group
differentiates our study from FAME-2 where FFR values
were known in all of the randomized patients.9Acknowledgements
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Standard care of NSTEMI patients in the National
Health Service
The participating hospitals adhere to current guide-
lines for optimal medical therapy1,3 and optimal
revascularization.1-3 A left main stenosis of ≥50% and
an epicardial coronary stenosis N70% are usually taken
to be obstructive lesions for which revascularization
should be considered.1,2 Patients who may be
candidates for CABG will be discussed at the Multi-
disciplinary Heart Team meeting. If staged PCI is
planned then all procedures should take place during
the index hospitalization.
Multidisciplinary heart team meeting
Patients with coronary disease amenable to CABG may
be referred to the multidisciplinary heart team meeting.
In the angiography-guided group, the FFR data will not be
disclosed at this meeting. For staged PCI, the recom-
mendation is for the second procedure to be performed
during the index admission. For CABG, the recommen-
dation is for surgery within 30 days of referral.
Myocardial FFR measurement
FFR is the ratio of distal coronary pressure to aortic
pressure measured during coronary hyperemia.7-12
According to eligibility criteria in the protocol (Table I),
FFR should be measured in all coronary arteries with one
or more stenoses ≥30% of the reference vessel diameter
based on visual assessment of the angiogram, with normal
coronary blood flow (TIMI grade III) and in the opinion of
the attending cardiologist FFR measurement will be
feasible and may have diagnostic value. Left main stem
disease is included and the upper limit for left main
stenosis severity is 80%. In order to facilitate the inclusion
of patients with complex disease, an FFR of 0.5 can be
assigned without requirement to pass the pressure wire
in occluded arteries, left main lesions N80% and critical
severe epicardial coronary lesions (e.g. N90% severity) in
which the cardiologist believes FFR has no diagnostic
value. This approach is intended to facilitate and
maximize the inclusion of all eligible patients.
FFR will be measured according to best practice as
described in the investigator guideline. The cardiologist
should pass the pressure wire across the target coronary
stenosis. The pressure wire (Certus, St Jude Medical,
Uppsala) is similar to the guidewires that are normally
used in PCI except that the wire has a pressure-sensitive
sensor 3 cm from its distal tip. The pressure wire will be
calibrated initially to ensure standardized measurements
and when positioned at the distal end of the guide
catheter the pressure wire recording will be equalized
with the aortic pressure. The wire is then passed into
the coronary artery of interest and advanced at least 6
cm distal to the coronary stenosis using standardtechniques. Once the marker is appropriately posi-
tioned and after an initial 2 minute rest period, an
intravenous infusion of adenosine (140 mcg/kg/min–
210 mcg/kg/min) via a central vein or large antecubital
vein is started to establish coronary hyperemia. Typical
changes in blood pressure (i.e. fall in systolic pressure
N10%), heart rate (i.e. rise in heart rate N20%) and
symptoms will be recorded prospectively to confirm a
hemodynamic response to adenosine during a period of
at least 2 minutes. When there is an inadequate response
with the standard dose of adenosine (140 mcg/kg/min)
then the dose can be increased up to 210 mcg/kg/min in
order to best ensure maximal hyperemia. If intravenous
adenosine is not tolerated then intracoronary adenosine
could be administered or FFR will be not be recorded
and this will be noted in the Case Report Form. Our
protocol has been developed according to previous
studies on the hemodynamic response to intravenous
adenosine when used for stress testing (online Appen-
dix Supplementary references).
Microvascular function
Coronary microvascular function is clinically-relevant
in NSTEMI19 and has prognostic importance.26,27 Pres-
sure wire-derived parameters of microcirculatory func-
tion can be easily obtained using thermodilution
techniques around the same time as the FFR measure-
ments. Therefore, wherever feasible, the index of
microcirculatory resistance (IMR) and the resistive
reserve ratio (RRR), a measure of microcirculatory
vasodilator capacity) will also be measured.19,26,27
Measurement of microvascular parameters will not affect
FFR measurements or blinding. In the angiography-
guided group, these data will be acquired by the
cardiologist who will be blind to the results which will be
recorded by the research team and not disclosed.
Trial management
Quality assurance of FFR and blinding during the index
procedure
The initial treatment decision will be prospectively
recorded before randomisation and any change to this
decision after randomization, such as after FFR disclosure
in the FFR-guided group will also be recorded prospec-
tively in the catheter laboratory during the procedure. At
this time, the protocol also requires prospective confir-
mation that in the 'angiography-guided control group',
the clinical team were blinded to the pressure wire
recordings and FFR values throughout. The investigator is
also required to confirm that the protocol was preserved.
Adherence to the blinding protocol will be monitored
with site visits.
The trial will be conducted in line with Guidelines for
Good Clinical Practice (GCP) in Clinical Trials.32 Trial
management will include a Trial Management Group
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October 2013(TMG), Trial Steering Committee (TSC), Clinical Event
Committee (CEC), and Data and Safety Monitoring Board
(DSMB) (online Appendix). Day to day study activity
will be coordinated by the TMG, which will be
responsible to the TSC. The TSC will be responsible for
overall trial supervision. In order to adjudicate and
validate adverse clinical events, source clinical data will
be reviewed by an independent CEC comprised of at
least 3 cardiologists. The DSMB will follow an agreed
charter prepared according to the DAMOCLES guide-
lines.33 The DSMB will have access to unblinded data
including the FFR results. The DSMB will include one
interventional and one non-interventional cardiologist
and a biostatistician (Chair), not affiliated to any of the
institutions involved in the study and therefore inde-
pendent of the study team. Progression during the study
will require approval from the DSMB after the 35th
randomized patient.Statistical methods
The sample size calculation, pilot data22 statistical and
health economic28,29 analyses plans are described in the
online Appendix Supplementary material.Sample size calculation
With 322 randomized subjects (161 subjects in the FFR
disclosed and non-disclosed groups), the study will have
90% power at a 5% level of significance to detect a 50%
relative increase in the proportion of patients assigned to
medical treatment in the disclosure group from about
15% to 30%. This difference is based on observations
made in a pilot study22 performed to inform the design of
the current trial. We have assumed zero loss to follow up
since the primary outcome is measured during the initial
procedure. Allowing for any technical difficulties or loss
of data at the time of the procedure the total sample size
will be 350 patients (Figure 1).
Approximately 1400 patients will be screened and 350
patients will be randomized in b2 years (Figure 1).
Potentially 25% of screened patients may be ineligible
(e.g. unsuitable for PCI or CABG). Some patients may not
wish to take part (~25%) and following initial angiogra-
phy a further 25% may be ineligible based on coronary
anatomy and disease resulting in 350 randomized
patients. We anticipate the rate of major adverse cardiac
events in the control group will be ~20% during ~1.5
years mean follow-up (or at least 35 events in 175
patients) such that the relationship between FFR and
cardiac outcome in NSTEMI can be evaluated. The
Glasgow Clinical Trials Unit (Robertson Centre for
Biostatistics) will act as an independent coordinating
center for data management and will conduct the
statistical analyses.Statistical analysis
The primary outcome of the between group difference
in the proportions of patients allocated to medical
therapy will be assessed using Fisher's Exact test and the
differences in proportions estimated with a 95% confi-
dence interval. The rate of discordance between FFR and
coronary stenosis severity assessments will be estimated
over all patients and segments and a 95% confidence
intervals calculated taking into account the within subject
clustering. Additional modelling will be carried out to
investigate evidence of heterogeneity in the rates of
discordance across segments. Rates of major coronary
events at 6 months, 12 months and 3 years will be
analyzed using logistic regression analysis. In addition
Kaplan-Meier time to event curves will be calculated to
describe the time course of events in each group. Rates of
the feasibility of FFR assessment and adverse events rates
will be summarized.
Health economics
A decision model will be constructed to reflect the
treatment of NSTEMI patients and the effects of the two
diagnostic options (FFR or the visual interpretation of the
angiogram alone).28,29 The model will be made probabi-
listic so as to characterise the uncertainty surrounding
parameter estimates and ultimately reflect uncertainty in
the cost-effectiveness estimate. The decision model can
then be run to estimate the cost-effectiveness of using
FFR measurements to guide clinical treatment decisions
compared to the use of angiography results alone in the
current trial. The health economic model in this
developmental study will also inform the design of a
future multicenter clinical trial.
Magnetic resonance imaging (MRI) sub-study
Since FFR is not validated in patients with unstable
coronary disease, we set up an MRI sub-study at the lead
site to determine the level of agreement between
inducible ischemia as revealed by stress MRI (a non-
invasive gold standard) and FFR. Study participants will
be invited to have an adenosine stress perfusion MRI at
3.0 Tesla before invasive angiography and/or within 10
days afterwards, and again at 6 months to assess left
ventricular remodeling and function. Clinicians will be
blinded to the MRI results which will not influence
catheter laboratory treatment decisions. The sub-study
has ethics approval and all patients will give written
informed consent.Supplementary References
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